Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eloralintide in Participants With Obesity or Overweight
NCT07738614Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of eloralintide in obesity (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Acetaminophen Area Under the Concentration Versus Time Curve at Day 65, Acetaminophen Maximum Observed Concentration at Day 65 and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
eloralintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07738614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738614.